There are several potential targets in the MMP-9 regulatory pathway for host-directed therapy in CNS-TB, and of note, both specific and broad-based MMP-inhibitors are currently being explored as adjunctive therapy in other CNS-diseases such as autoimmune encephalomyelitis and stroke [30, 31]. Here, MMP9 is linked to tuberculosis.